Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Christopher Dakhil (NPI 1972721348)

Field	Value
Entity Type	Individual
Organization	Christopher Dakhil
Address	818 N Emporia St Ste 403
City	Wichita
State	KS
ZIP	67214
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 23, 2007

Payer Source	Total Paid
Medicare	$4.4M
Medicaid	$0

Key Findings

This provider is effectively a single-payer Medicare practice: lifetime Medicare revenue is $4.4M and there is no Medicaid billing on file, indicating operations and revenue are heavily concentrated in the Medicare population rather than serving Medicaid beneficiaries. Analysts should treat payer mix as Medicare-dominant when modeling patient sources, reimbursement risk, and network placement.

Revenue concentration is high among a few drug/injection codes: the top 3 Medicare codes by revenue account for 57.9% of total Medicare revenue, with J9271 alone representing $1.5M (35.8% of Medicare revenue). This concentration implies the practice’s financial performance is heavily dependent on a small set of high-cost oncology/immunotherapy agents.

The code mix shows a specialty focus on oncology and biologic oncology therapies: highest-revenue codes include J9271 (pembrolizumab), J9299 (nivolumab), and J0897 (denosumab), plus other immunotherapy and antineoplastic agents like J9173, J9022, and J9145. Combined with chemotherapy administration code 96413 and frequent E/M codes (99214, 99213), the pattern indicates the provider operates as an oncology infusion/medical oncology practice delivering systemic cancer therapies and associated office-based care.

Competitive standing is mixed but includes notable national concentration for several codes: the provider ranks in the 96th percentile nationally for J9271 (rank #64 of 1841), and also appears as an extreme outlier for 96413 (98th percentile, rank #114 of 7514), indicating above-typical national volumes for key chemotherapy and immunotherapy administration services. At the same time, several other oncology drug codes show typical or modest national rank positions, so the practice is a strong national-volume participant for a subset of agents rather than across the full oncology drug portfolio.

There are multiple statistical high-volume signals that warrant attention for benchmarking and network contracting: beyond J9271, the provider is described as "notably above typical national volume" for J1627 and J0185 and as an "extreme outlier" for 99205 and 96413. These notations suggest unusually high utilization of certain supportive meds, infusion encounters, and complex office visits relative to peers, which may affect utilization review and value-based care arrangements.

Operational profile and service mix extend beyond drug administration to imaging and supportive care: the dataset includes high-paid imaging claims (78815 and 78816 PET/CT entries) and supportive agents like J1568 (IVIG) and Q5108/Q5115 biosimilars (pegfilgrastim, rituximab biosimilars). This indicates the practice coordinates diagnostic imaging and a range of biologic and supportive therapies, consistent with a comprehensive oncology clinic model.

Provider tenure is long-standing in Medicare: NPI enumeration date is 2007-04-23 (~19 years ago), so the clinician has an extended Medicare billing history to analyze for trend, referral, and volume stability over time. That tenure supports using longitudinal Medicare claims to assess practice growth, shifts in drug mix, or changes in care intensity.

Because there is no Medicaid activity on file, comparisons to in-state Medicaid peers are not applicable for contracting or market-share work; analysts should rely on Medicare-based competitive benchmarks for this clinician when evaluating market position, utilization, and reimbursement performance.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

100 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	34,800	$40	$1.5M
J9299	Injection, nivolumab, 1 mg	28,140	$20	$675.4K
J0897	Injection, denosumab, 1 mg	13,980	$20	$251.6K
J1930	Injection, lanreotide, 1 mg	5,280	$40	$227K
J9173	Injection, durvalumab, 10 mg	3,230	$60	$200.1K
J9022	Injection, atezolizumab, 10 mg	2,930	$60	$187.4K
J9145	Injection, daratumumab, 10 mg	3,020	$50	$145K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	110	$1,070	$118.3K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	4,300	$20	$98.9K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,860	$30	$97.2K

Showing 1–10 of 100

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 100 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Christopher Dakhil — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

100 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	20	28,900	$40	$1.1M
J9299	6	10	24,550	$20	$637.2K
J1930	6	10	9,180	$40	$402.7K
J9145	10	10	6,660	$50	$394.7K
J9022	6	10	3,910	$60	$301.1K
J9173	4	10	3,480	$60	$230.3K
J1568	10	10	3,690	$30	$129K
Q5107	6	10	4,440	$20	$106.5K
Q5115	7	10	2,340	$30	$92.9K
J9264	5	10	6,930	$10	$89.7K

Showing 1–10 of 100

Related Providers

Other providers that share a Tax Identification Number (TIN) with Christopher Dakhil, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0
Shaker Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Christopher Dakhil, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Craig Resources LLC	KS	Home Health Agency	$0	$97.3M
Paradigm Services Inc	KS	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$42.4M
Wesley Medical Center LLC	KS	General Acute Care Hospital	$0	$30.2M
Gracemed Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$18.3M
Healthcore Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$15.3M
Diversified Family Services LLC	KS	Home Health Agency	$0	$13.9M
Alpha Service	KS	Developmentally Disabled Services Day Training Agency	$0	$12.1M
Carepoint Emergency Medicine Kansas LLC	KS	Emergency Medicine Physician	$0	$11.8M
Hunter Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$10.4M
Ascension Via Christi Hospitals Wichita Inc.	KS	General Acute Care Hospital	$0	$8.9M

Christopher Dakhil — Billing Profile & Reimbursement Data

Sign up for Christopher Dakhil — Billing Profile & Reimbursement Data policy alerts

Christopher Dakhil — Billing Profile & Reimbursement Data

Sign up for Christopher Dakhil — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References